Codexis(US:CDXS) ZACKS·2025-05-14 22:40分组1 - Codexis reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and compared to a loss of $0.16 per share a year ago, indicating a significant earnings surprise of -25% [1] - The company generated revenues of $7.54 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.99%, and a decline from year-ago revenues of $17.07 million [2] - Codexis shares have decreased by approximately 46.3% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] 分组2 - The earnings outlook for Codexis is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Codexis is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $14.68 million, and for the current fiscal year, it is -$0.62 on revenues of $65.74 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Codexis belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8] - Roivant Sciences Ltd., another company in the same industry, is expected to report a quarterly loss of $0.16 per share, reflecting a year-over-year change of +30.4%, with revenues projected to be $67.33 million, up 132.7% from the previous year [9]